

## ABSTRACT

Specific binding members comprising human antibody antigen binding domains specific for human transforming growth factor beta (TGF $\beta$ ) bind specifically isoforms TGF $\beta$ 2 and TGF $\beta$ 1 or both, preferentially compared with TGF $\beta$ 3. Specific binding members may be isolated and utilized in the treatment of disease, particularly fibrotic disease and also immune/inflammatory diseases. Therapeutic utility is demonstrated using *in vitro* and *in vivo* models. Full sequence and binding information is provided, including epitope sequence information for particularly advantageous specific binding member which binds the active form of TGF $\beta$ 2, neutralizing its activity, but does not bind the latent member.